Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2020 Apr 11;47(12):2765–2775. doi: 10.1007/s00259-020-04784-0

Fig. 2.

Fig. 2

ImmunoPET imaging of ICAM-1-positive melanomas. a 64Cu-NOTA-ICAM-1 immunoPET imaging of A375-bearing nude mice. Serial maximum intensity projection images of a representative mouse at different imaging time-points were given. b Region of interest analysis of 64Cu-NOTA-ICAM-1 immunoPET imaging data. c Biodistribution study at 48 h post-injection of 64Cu-NOTA-ICAM-1. d 64Cu-NOTA-IgG immunoPET imaging of A375-bearing nude mice. Serial maximum intensity projection images of a representative mouse at different imaging time-points were given. e Region of interest analysis of 64Cu-NOTA-IgG immunoPET imaging data. f Biodistribution study at 48 h post-injection of 64Cu-NOTA-IGg. g Immunofluorescent imaging of a representative A375 tumor. The tumor section was stained for CD31 (red), ICAM-1 (green), and nuclei (blue). The tumors were indicated by yellow dotted circles